ReviewFrontiers in pharmacology2026
Rewiring macrophage immunometabolism in gouty arthritis: from metabolic checkpoints to intelligent nano-delivery.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunometabolic regulation in gouty arthritis: current evidence, mechanistic insights, and remaining challenges.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gouty arthritis (GA) is driven by NLRP3 inflammasome activation, yet its underlying metabolic mechanisms remain poorly explored. Current therapies focus on uric acid reduction and anti-inflammation, often overlooking the plasticity of macrophages controlled by metabolic reprogramming. This review systematically dissects the metabolic shifts in GA, particularly the transition from oxidative phosphorylation (OXPHOS) to glycolysis (Warburg effect) and the unique role of lipid/amino acid metabolism. We describe macrophage immunometabolism, tricarboxylic acid (TCA)cycle breakpoints, and metabolite functions, with particular emphasis on the "metabolic-epigenetic" axis (e.g., lactate conversion). We summarize emerging nanotherapeutic strategies (e.g., nanoenzymes, biomimetic carriers) precisely targeting these metabolic checkpoints. Current reviews on GA primarily focus on conventional anti-inflammatory and uric acid-lowering strategies. However, although macrophages are central drivers of the GA disease process, the mechanisms underlying the coupling of their metabolic reprogramming and polarization have not yet been fully elucidated. In particular, metabolite-mediated "metabolic-epigenetic" crosstalk, as well as how to precisely regulate these metabolic targets using emerging nanotargeting technologies, remain blind spots in current research. This paper is the first to systematically integrate these dimensions, aiming to fill this gap by exploring novel nanostrategies and future prospects for treating GA through the remodeling of macrophage immunometabolism. Targeting macrophage metabolism offers a paradigm shift for GA-from conventional symptom management to targeted disease resolution by directly inhibiting glycolytic flux and succinate accumulation, thereby repolarizing pro-inflammatory M1 macrophages into the tissue-repairing M2 phenotype.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.